Health Canada approves BLEScath^® for use in Canada.

Product Update

Health Canada approves BLEScath^® for use in Canada.

BLEScath^® is intended for the administration of bovine lipid extract surfactant suspension (BLES^®) using minimally invasive surfactant therapy (MIST) / less invasive surfactant administration (LISA) technique for rescue treatment of infants with Neonatal Respiratory Distress Syndrome (NRDS)^2,3.  BLEScath^® is a first-of-its-kind single-use, unique, intratracheal, thin catheter with an integrated stylet that is anchored and remains fixed in place.

BLES^® is intended for neonates at ≥ 28 weeks and or ≥ 1000 grams who do not require intubation or mechanical ventilation and meet the criteria for surfactant administration (i.e., oxygenation requirement met)¹.

Citations

1.BLES® Product Monograph, January 31, 2022.

2.BLEScath^® Instructions for Use (IFU) December 31, 2020.

3.Herting E, Härtel C, Göpel W. Less invasive surfactant administration. Current Opinion in Pediatrics.2020;32(2):228–34.